Retatrutide vs Mazdutide

Retatrutide wins for raw potency, maximum fat loss per week, and unsurpassed visceral/liver fat clearing—delivering up to 24% weight reduction with energy expenditure increases not matched by dual agonists. It also offers a broader mechanistic spectrum with GLP-1, GIP, and glucagon activity for metabolic flexibility beyond pure anorexia.

Mazdutide wins for cleaner side-effect profile, established dosing regimens from phase 3 trials (GLORY-1), greater accessibility (especially in Asian research markets), and solid real-world data for users prioritizing sustainable recomp and hepatic fat clearance without the more aggressive heart rate and GI effects often seen at peak retatrutide dosages.

Pick Retatrutide if:

• The goal is maximum, rapid weight/fat loss—especially where 15%+ reduction is desired
• There's a priority on aggressive visceral and hepatic fat clearance (post-orals, NAFLD risk, extreme cuts)
• Protocols have already plateaued on tirzepatide or mazdutide and need a stronger mechanism
• Appetite suppression alone isn't enough—higher baseline energy expenditure is needed
• Willing to manage a more intense titration and GI side effect profile for superior efficacy

Pick Mazdutide if:

• A balanced, sustainable recomp tool is preferred—14% weight loss with milder sides
• Liver fat reduction and enzyme normalization are top priorities
• Prior experience with GLP-1 mono-therapy was limited by cognitive side effects or lethargy
• Proven dosing ladders and more accessible research-grade supply are desired
• Lower risk profile is favored over bleeding-edge maximal efficacy